Jean-Marie Ouedraogo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-Marie Ouedraogo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Younes Rahali
Mohammed V University of Rabat
7 shared publications- Soumaya El Baraka
Department of Drug Science, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakesh, Morocco
6 shared publications - Ali Cherif Chefchaouni
Laboratory of drug sciences, Department of Pharmacy, Faculty of Medicine, Pharmacy, and Dental Medicine of Fez, Sidi Mohamed Ben Abdellah University, Fez, Morocco
5 shared publications Mohammed Jaouad Belahcen
National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco
3 shared publicationsMohammed-Jaouad Belahcen
National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco
3 shared publicationsAbou Sessouma
Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
2 shared publications
Latest Publications
- 3 August 2026
- Published by Wiley in Process Safety Progress
Optimization of Explosive Atmospheres Hazardous Area Classification in Pharmaceutical Liquid Manufacturing Using a Semi‐Empirical Ventilation‐Based Approach
Explosive ATmospheres (ATEX) zoning in process industries is commonly based on standards such as International Electrotechnical Commission (IEC) 60079‐10‐1. However, when ventilation performance is not quantitatively evaluated, their practical application may result in conservative estimations of hazardous volumes, particularly in highly ventilated environments. A semi‐empirical methodology integrating evaporation rate modeling and ventilation performance is proposed to quantify vapor generation and determine the minimum ventilation rate required to maintain concentrations below 25% of the lower explosive limit. The approach is applied to a pharmaceutical facility using ethanol with an air exchange rate of 25 vol h −1 . The vapor generation rate is estimated at 2.01 m 3 h −1 , leading to a critical ventilation rate of about 244 m 3 h −1 . For the studied configuration (170 m 3 ), the actual ventilation rate exceeds this threshold, with a safety factor (Qreal/Qmin) of approximately 17.4. The results indicate that large‐scale vapor accumulation is unlikely under the studied ventilation conditions, although localized transient flammable atmospheres may still occur near potential release sources. The results show that explicitly accounting for ventilation performance allows a reduction in the conservatism of ATEX zoning while maintaining an adequate safety factor. The proposed methodology provides a practical framework for risk‐informed hazardous area classification in ventilated industrial environments.
- 3 August 2026
- Published by Wiley in Process Safety Progress
Optimization of Explosive Atmospheres Hazardous Area Classification in Pharmaceutical Liquid Manufacturing Using a Semi‐Empirical Ventilation‐Based Approach
Explosive ATmospheres (ATEX) zoning in process industries is commonly based on standards such as International Electrotechnical Commission (IEC) 60079‐10‐1. However, when ventilation performance is not quantitatively evaluated, their practical application may result in conservative estimations of hazardous volumes, particularly in highly ventilated environments. A semi‐empirical methodology integrating evaporation rate modeling and ventilation performance is proposed to quantify vapor generation and determine the minimum ventilation rate required to maintain concentrations below 25% of the lower explosive limit. The approach is applied to a pharmaceutical facility using ethanol with an air exchange rate of 25 vol h −1 . The vapor generation rate is estimated at 2.01 m 3 h −1 , leading to a critical ventilation rate of about 244 m 3 h −1 . For the studied configuration (170 m 3 ), the actual ventilation rate exceeds this threshold, with a safety factor (Qreal/Qmin) of approximately 17.4. The results indicate that large‐scale vapor accumulation is unlikely under the studied ventilation conditions, although localized transient flammable atmospheres may still occur near potential release sources. The results show that explicitly accounting for ventilation performance allows a reduction in the conservatism of ATEX zoning while maintaining an adequate safety factor. The proposed methodology provides a practical framework for risk‐informed hazardous area classification in ventilated industrial environments.
- 6 April 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Stability challenges of oncological medicines: The overlooked role of industrial pharmacy
Background: Ensuring the stability and quality of oncological medicines remains a major challenge across both industrial and hospital settings. These products are often biologics or highly sensitive compounds are vulnerable to chemical, physical, and microbiological degradation pathways that can compromise therapeutic efficacy and patient safety. Objective: This review provides an overview of the main stability challenges associated with oncological medicines and highlights the complementary roles of industrial pharmacy and hospital pharmacy in preventing degradation, contamination, and handling-related risks. Discussion: Chemical degradation mechanisms including oxidation, deamidation, acylation, and photo-induced reactions are particularly prominent in peptides, monoclonal antibodies, and antibody–drug conjugates. Physical instability, driven by temperature fluctuations or hydrophobic payloads in ADCs (, can promote aggregation and reduce shelf-life. Microbiological instability remains a critical concern, especially in immunocompromised patients, and underscores the importance of controlled environments, aseptic technique, and compliance with sterility and endotoxin standards. Contamination risks particulate, microbiological, or cross-contamination are markedly lower when oncological medicines are prepared in ISO-classified clean rooms, isolators, or closed-system transfer devices (CSTDs). Post-reconstitution stability is equally dependent on strict cold-chain management, appropriate conditioning, and optimized clinical workflows. Robotic compounding systems further enhance safety by improving precision, reducing environmental exposure, and strengthening traceability. Conclusion: Stability preservation for oncological medicines requires an integrated approach that bridges industrial formulation strategies, advanced manufacturing technologies, and rigorously controlled hospital practices. Strengthening the collaboration between industry and clinical pharmacy is essential to ensure the quality, safety, and therapeutic performance of anticancer treatments.
- 6 April 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Stability challenges of oncological medicines: The overlooked role of industrial pharmacy
Background: Ensuring the stability and quality of oncological medicines remains a major challenge across both industrial and hospital settings. These products are often biologics or highly sensitive compounds are vulnerable to chemical, physical, and microbiological degradation pathways that can compromise therapeutic efficacy and patient safety. Objective: This review provides an overview of the main stability challenges associated with oncological medicines and highlights the complementary roles of industrial pharmacy and hospital pharmacy in preventing degradation, contamination, and handling-related risks. Discussion: Chemical degradation mechanisms including oxidation, deamidation, acylation, and photo-induced reactions are particularly prominent in peptides, monoclonal antibodies, and antibody–drug conjugates. Physical instability, driven by temperature fluctuations or hydrophobic payloads in ADCs (, can promote aggregation and reduce shelf-life. Microbiological instability remains a critical concern, especially in immunocompromised patients, and underscores the importance of controlled environments, aseptic technique, and compliance with sterility and endotoxin standards. Contamination risks particulate, microbiological, or cross-contamination are markedly lower when oncological medicines are prepared in ISO-classified clean rooms, isolators, or closed-system transfer devices (CSTDs). Post-reconstitution stability is equally dependent on strict cold-chain management, appropriate conditioning, and optimized clinical workflows. Robotic compounding systems further enhance safety by improving precision, reducing environmental exposure, and strengthening traceability. Conclusion: Stability preservation for oncological medicines requires an integrated approach that bridges industrial formulation strategies, advanced manufacturing technologies, and rigorously controlled hospital practices. Strengthening the collaboration between industry and clinical pharmacy is essential to ensure the quality, safety, and therapeutic performance of anticancer treatments.
- 18 December 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (1) , 49-57
Optimizing chemotherapy medication leftover management circuit in a centralized chemotherapy preparation unit: A comprehensive FMECA risk analysis and continuous improvement approach
Objective: Chemotherapy medications are usually having high costs, and new targeted drugs can be especially expensive, representing a challenge on healthcare, particularly in low- and middle-income countries. As cytotoxic leftover management is crucial for reducing medication wastage, the aim of this study is to evaluate and optimize leftover management circuit in NIO’S Pharmacy Centralized Chemotherapy Preparation Unit (CCPU) through a Failure Mode, Effects and Criticality Analysis (FMECA), and propose continuous improvement element to enhance the security of the process. Method: The FMECA were conducted in NIO’s CCPU from March to May 2023, then continuous improvement plan was established to enhance the security of the process. The failure modes, their causes, impact, and criticality were assessed through criticality index calculation (CI = severity × frequency × detectability), and the risk concerned safety and effectiveness disruptions in chemotherapy preparation circuit using cytotoxic leftover. Results: Leftover management circuits were described in flowchart form, where 18 failure modes were detected in four different steps of the process from chemotherapy preparation to disposal. Failure with highest critical index were detected in the case of equipment malfunction, improper storage temperature, and humidity. Continuous improvement recommendations were proposed in a table form. Conclusion: FMECA analysis applied to NIO’s chemotherapy leftover management process allowed us to evaluate, secure, and optimize the circuit, and to propose several actions to implement in a perspective of continuous improvement.
- 18 December 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (1) , 49-57
Optimizing chemotherapy medication leftover management circuit in a centralized chemotherapy preparation unit: A comprehensive FMECA risk analysis and continuous improvement approach
Objective: Chemotherapy medications are usually having high costs, and new targeted drugs can be especially expensive, representing a challenge on healthcare, particularly in low- and middle-income countries. As cytotoxic leftover management is crucial for reducing medication wastage, the aim of this study is to evaluate and optimize leftover management circuit in NIO’S Pharmacy Centralized Chemotherapy Preparation Unit (CCPU) through a Failure Mode, Effects and Criticality Analysis (FMECA), and propose continuous improvement element to enhance the security of the process. Method: The FMECA were conducted in NIO’s CCPU from March to May 2023, then continuous improvement plan was established to enhance the security of the process. The failure modes, their causes, impact, and criticality were assessed through criticality index calculation (CI = severity × frequency × detectability), and the risk concerned safety and effectiveness disruptions in chemotherapy preparation circuit using cytotoxic leftover. Results: Leftover management circuits were described in flowchart form, where 18 failure modes were detected in four different steps of the process from chemotherapy preparation to disposal. Failure with highest critical index were detected in the case of equipment malfunction, improper storage temperature, and humidity. Continuous improvement recommendations were proposed in a table form. Conclusion: FMECA analysis applied to NIO’s chemotherapy leftover management process allowed us to evaluate, secure, and optimize the circuit, and to propose several actions to implement in a perspective of continuous improvement.
- 20 September 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 30 (7) , 1152-1159
Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology
Objective: Most intravenous anticancer drugs are administered in a dose per unit area or body weight, if not promptly administered to another patient cytotoxic leftover would be destroyed. To contain wastage, low-cost measures are highly desirable to contain and reduce expenditures without impairing the quality of care. The objective of the study is to evaluate the cost saved through the use of the two cytotoxic waste management techniques implemented in National Institute of Oncology’s centralized chemotherapy preparation unit, vial sharing and dose rounding. Method: A 6-month prospective single centre study from 1 February to 1 August 2023 at the National Institute of Oncology of Rabat in Morocco. The number of prepared preparations and amount of drug saved by both vial sharing and dose rounding was collected using the centralized chemotherapy preparation unit’s ‘leftover tracking file’, the corresponding cost saved were calculated and then compared for each technique and with 2018 results. Results: In total, 18,218 preparations were considered in the 6-month study. With the vial sharing technique 636,524.5 mg were saved corresponding to 246,031.4 (USD) saved cost, against 212,838.4 mg by dose rounding corresponding to 75,598.5 (USD) saved cost. This saving corresponded to a total of 321,629.4 (USD). Compared to the 2018 results leftovers costs saved by vial sharing corresponded to 289,972.05 (USD) by vial sharing technique for 1-year extrapolated period, and this study shows a saved cost of 321,629.9 (USD) by both vial sharing and dose rounding techniques. Conclusion: Dose rounding technique combined with vial sharing allowed National Institute of Oncology’s centralized chemotherapy preparation unit to limit expensive cytotoxic cost wastage, highlighting these technique benefits.
- 20 September 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 30 (7) , 1152-1159
Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology
Objective: Most intravenous anticancer drugs are administered in a dose per unit area or body weight, if not promptly administered to another patient cytotoxic leftover would be destroyed. To contain wastage, low-cost measures are highly desirable to contain and reduce expenditures without impairing the quality of care. The objective of the study is to evaluate the cost saved through the use of the two cytotoxic waste management techniques implemented in National Institute of Oncology’s centralized chemotherapy preparation unit, vial sharing and dose rounding. Method: A 6-month prospective single centre study from 1 February to 1 August 2023 at the National Institute of Oncology of Rabat in Morocco. The number of prepared preparations and amount of drug saved by both vial sharing and dose rounding was collected using the centralized chemotherapy preparation unit’s ‘leftover tracking file’, the corresponding cost saved were calculated and then compared for each technique and with 2018 results. Results: In total, 18,218 preparations were considered in the 6-month study. With the vial sharing technique 636,524.5 mg were saved corresponding to 246,031.4 (USD) saved cost, against 212,838.4 mg by dose rounding corresponding to 75,598.5 (USD) saved cost. This saving corresponded to a total of 321,629.4 (USD). Compared to the 2018 results leftovers costs saved by vial sharing corresponded to 289,972.05 (USD) by vial sharing technique for 1-year extrapolated period, and this study shows a saved cost of 321,629.9 (USD) by both vial sharing and dose rounding techniques. Conclusion: Dose rounding technique combined with vial sharing allowed National Institute of Oncology’s centralized chemotherapy preparation unit to limit expensive cytotoxic cost wastage, highlighting these technique benefits.
- 16 November 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 125-129
Retrospective analysis of failures of ambulatory elastomeric pumps containing 5-FU in a hospital pharmacy unit
Introduction: Ambulatory chemotherapy is an important and major advance in clinical oncology practice since it allows the administration of chemotherapy in the comfort of the patient's home without the assistance of a health professional by means of an elastomeric pump. However, these pumps are not without risks and can be the cause of incidents due to technical failures. Our objective is to study the technical failures of elastomeric pumps in the Cytotoxic Preparation Unit and in the patient's home, to evaluate the possible impact of these failures on the patient and on the staff and to propose measures to reduce them. Materials and methods: This is a retrospective study conducted at the pharmacy of the National Institute of Oncology in Rabat. It gathered all the specific reports on elastomeric pumps issued during the period (January 2017–May 2021) by the cytotoxic preparation unit to the materiovigilance cell via a notification form. Results: 205 cases of elastomeric pump materialovigilance were identified during the study period. The main technical failures were: chemotherapy product leakage (44%), flow rate anomalies (30%) and injection difficulties (20%). Following these incidents, certain actions were undertaken such as alerts sent to the supplier and letters sent to the competent health authorities. Conclusion: Despite the failures that may have occurred, elastomeric pumps have revolutionized home chemotherapy delivery. They are considered reliable, consistent, easy to use and handle, and are well accepted in the population.
- 16 November 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 125-129
Retrospective analysis of failures of ambulatory elastomeric pumps containing 5-FU in a hospital pharmacy unit
Introduction: Ambulatory chemotherapy is an important and major advance in clinical oncology practice since it allows the administration of chemotherapy in the comfort of the patient's home without the assistance of a health professional by means of an elastomeric pump. However, these pumps are not without risks and can be the cause of incidents due to technical failures. Our objective is to study the technical failures of elastomeric pumps in the Cytotoxic Preparation Unit and in the patient's home, to evaluate the possible impact of these failures on the patient and on the staff and to propose measures to reduce them. Materials and methods: This is a retrospective study conducted at the pharmacy of the National Institute of Oncology in Rabat. It gathered all the specific reports on elastomeric pumps issued during the period (January 2017–May 2021) by the cytotoxic preparation unit to the materiovigilance cell via a notification form. Results: 205 cases of elastomeric pump materialovigilance were identified during the study period. The main technical failures were: chemotherapy product leakage (44%), flow rate anomalies (30%) and injection difficulties (20%). Following these incidents, certain actions were undertaken such as alerts sent to the supplier and letters sent to the competent health authorities. Conclusion: Despite the failures that may have occurred, elastomeric pumps have revolutionized home chemotherapy delivery. They are considered reliable, consistent, easy to use and handle, and are well accepted in the population.
- 1 September 2021
- Published by Elsevier in Le Pharmacien Hospitalier et Clinicien
- Vol. 56 (3) , 282-290
Dose readjustment of sterile preparations to optimize the reuse of non-administered anticancer agents
- 1 September 2021
- Published by Elsevier in Le Pharmacien Hospitalier et Clinicien
- Vol. 56 (3) , 282-290
Dose readjustment of sterile preparations to optimize the reuse of non-administered anticancer agents
- 3 May 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (5) , 1093-1101
Economic impact of implementation of an automated drug supplying and management system in a Central Chemotherapy Preparation Unit in a Moroccan hospital
Objective: Automated Drug Supplying and management System (ADS) are effective devices that secure drug’s circuit and reduce hospital’s expenses. The purposes of this study are to estimate the earnings made from ADS through a cost-benefit medical economic study, to highlight its impact on Central Chemotherapy Preparation Unit’s (CCPU) global organization, its ergonomy and staff’s satisfaction. Method: Measurement of cytotoxic drug’s consumption, expiration losses, pharmacy staff’s working time, drugs stock-out before and after the implementation of ADS on the one hand, and assess its ergonomy and acceptability by users on the other hand. Results: After the implementation of ADS, cytotoxic drug’s consumption decreased by 9 (%), expiration losses by 98.3 (%), and we could see a gain in working time among CCPU’S technicians of 1.32 (h/day) and pharmacist of 0.67 (h/day), in contrast to the stock manager who increased his working time by 0.95 (h/day). Stock-out have decreased by 41.1 (%). The cost-benefit analysis has shown a net benefit of 67,437 between the two six-month phases, which corresponds to an economy of 134,874 (USD) over one year. The ADS was generally appreciated by the CCPU and pharmaceutical staff and 93(%) don’t want to return to the old system. Conclusion: ADS implementation within CCPU led to financial savings in the hospital, an optimization of expenses and better pharmaceutical management.
- 3 May 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (5) , 1093-1101
Economic impact of implementation of an automated drug supplying and management system in a Central Chemotherapy Preparation Unit in a Moroccan hospital
Objective: Automated Drug Supplying and management System (ADS) are effective devices that secure drug’s circuit and reduce hospital’s expenses. The purposes of this study are to estimate the earnings made from ADS through a cost-benefit medical economic study, to highlight its impact on Central Chemotherapy Preparation Unit’s (CCPU) global organization, its ergonomy and staff’s satisfaction. Method: Measurement of cytotoxic drug’s consumption, expiration losses, pharmacy staff’s working time, drugs stock-out before and after the implementation of ADS on the one hand, and assess its ergonomy and acceptability by users on the other hand. Results: After the implementation of ADS, cytotoxic drug’s consumption decreased by 9 (%), expiration losses by 98.3 (%), and we could see a gain in working time among CCPU’S technicians of 1.32 (h/day) and pharmacist of 0.67 (h/day), in contrast to the stock manager who increased his working time by 0.95 (h/day). Stock-out have decreased by 41.1 (%). The cost-benefit analysis has shown a net benefit of 67,437 between the two six-month phases, which corresponds to an economy of 134,874 (USD) over one year. The ADS was generally appreciated by the CCPU and pharmaceutical staff and 93(%) don’t want to return to the old system. Conclusion: ADS implementation within CCPU led to financial savings in the hospital, an optimization of expenses and better pharmaceutical management.
- 1 December 2020
- Published by Elsevier in Le Pharmacien Hospitalier et Clinicien
- Vol. 55 (4) , 315-321
Stockage des dispositifs médicaux après stérilisation : détermination d’une date limite d’utilisation
- 1 December 2020
- Published by Elsevier in Le Pharmacien Hospitalier et Clinicien
- Vol. 55 (4) , 315-321
Stockage des dispositifs médicaux après stérilisation : détermination d’une date limite d’utilisation
- 13 July 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 863-870
Risk reduction in a cancer chemotherapy production unit: Contribution of an automated drug dispensing system
Objective: The purpose of our study was to evaluate the contribution of an automated drug dispensing system in securing cancer chemotherapy production process at the pharmacy of the National Institute of Oncology in Rabat. Methods: The failure modes and effects analysis method was applied to the chemotherapy production process in two phases: Phase 1, using an open shelf for storage then phase 2, using an automated drug dispensing system. The failure modes were defined and their criticality indexes was calculated on the basis of the likelihood of occurrence, the potential severity for the patients and/or the impact on the process and the detection probability. The criticality indexes of the two phases were prioritized and compared. Results: We identified 35 failure modes for phase 1 and 37 for phase 2. The sum of criticality indexes was 5957 and 4586, respectively, for phase 1 and phase 2, corresponding to a criticality reduction of −23%. The greatest improvements concerned that the needed drug is missing during the picking, storage of potential expired drugs, and double compounding. Conclusion: Our study highlighted the contribution of automated drug dispensing system in risk minimization. The use of automated drug dispensing system is a part of security improvement in chemotherapy production unit.
- 13 July 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 863-870
Risk reduction in a cancer chemotherapy production unit: Contribution of an automated drug dispensing system
Objective: The purpose of our study was to evaluate the contribution of an automated drug dispensing system in securing cancer chemotherapy production process at the pharmacy of the National Institute of Oncology in Rabat. Methods: The failure modes and effects analysis method was applied to the chemotherapy production process in two phases: Phase 1, using an open shelf for storage then phase 2, using an automated drug dispensing system. The failure modes were defined and their criticality indexes was calculated on the basis of the likelihood of occurrence, the potential severity for the patients and/or the impact on the process and the detection probability. The criticality indexes of the two phases were prioritized and compared. Results: We identified 35 failure modes for phase 1 and 37 for phase 2. The sum of criticality indexes was 5957 and 4586, respectively, for phase 1 and phase 2, corresponding to a criticality reduction of −23%. The greatest improvements concerned that the needed drug is missing during the picking, storage of potential expired drugs, and double compounding. Conclusion: Our study highlighted the contribution of automated drug dispensing system in risk minimization. The use of automated drug dispensing system is a part of security improvement in chemotherapy production unit.